Myxomatous mitral valve disease is the most common cardiac disease in dogs, with evidence-based management strategies significantly extending comfortable life.
MMVD progresses from an asymptomatic murmur to congestive heart failure with exercise intolerance, coughing, and breathlessness. Each stage significantly affects quality of life. The EPIC trial demonstrated that beginning pimobendan before overt heart failure significantly extends comfortable life - a major welfare advance. Dogs in heart failure require careful balancing of multiple medications, salt restriction, and exercise modification. Owner education about monitoring resting respiratory rate at home enables early detection of decompensation.